E-Learning

On Thursday, Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z. These therapies target hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis, respectively. Intellia prioritized NTLA-2002 and nex-z while discontinuing the NTLA-3001 program and other early-stage initiatives. The reorganization will result in a 27% workforce reduction and a projected $8 million restructuring char

Wall Street's most watched gauge of investor anxiety rose to a three-week high on Friday as stock indexes sold off following a an upbeat jobs report that pushed back market expectations for further Federal Reserve interest rate cuts. The Cboe Volatility Index - an options-based indicator that reflects demand for protection against drops in the stock market - was last up 1.1 points to 19.18. A reading of 20 or higher on the VIX is associated with robust demand for options protection.

The Nasdaq Composite has gained 34.1% in the past 12 months, while Ark Innovation ETF returned 19.1%.

Delta Air Lines bills itself as the "premium" U.S. airline. Passengers appear to be buying in.

On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events reported. At intermediate doses in the trial (38.1 mg/m2 to 67.4 mg/m2), the confirmed objective response rate among evaluable patients was 23% (6 of 26 patients) across all B7-H4 high tumors and 23% (3 of 13 patients) with B7-H4 high TNBC, all of whom had

Constellation Brands shares plunged Friday, after the maker of beer, wine, and spirits cut its guidance as consumers held back spending.

The long-struggling chain reported better-than-expected revenue for its Q1 2025, although operating losses grew as it plans to shutter over a thousand locations.

On Friday, Invivyd Inc. (NASDAQ:IVVD) announced that new in vitro neutralization data show continued neutralizing activity of Pemgarda (pemivibart) and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC. The stock is trading with a strong session volume of 12.3 million, compared to an average volume of 757.02k as per data from Benzinga Pro. As anticipated, the data are largely consistent with those previously reported for KP.3.1.1, based on the structural biology of pemivibart an

(Bloomberg) -- A hectic week for UK bond and currency traders came to an end with yields stuck near the highest levels in years and the pound at its weakest since late 2023.Most Read from BloombergWhat Robotaxis Brought San FranciscoA Blueprint for Better Bike LanesNYC Condo Owners May Bear Costs of Landmark Green Building LawAmbitious High-Speed Rail Plans Advance in the Baltic RegionNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeGilts and sterling fell again on Friday after

U.S. equities slumped at midday after the December jobs report came in higher than anticipated, putting more Federal Reserve rate cuts in doubt.